Author: Benzinga Newsdesk | August 07, 2025 06:25am
ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.09) by 39.53 percent. This is a 300 percent decrease over losses of $(0.03) per share from the same period last year.